艾美捷特约代理ATGen重组蛋白产品。

Atgen公司成立于2002年，主要从事重组蛋白和抗体的研发、生产。目前，Atgen为世界范围内的客户提供产品，包括神经蛋白，热休克蛋白，酶，泛素蛋白相关蛋白，病毒抗原，抗体和激素及相关抗体产品。

ATGen was founded in 2002 on the belief that ‘Health is the greatest wealth’. The company and its employees are committed to both improving quality of life and saving lives—whether by providing novel diagnostic tests, developing new therapies, or providing the research community with quality proteins and antibodies that are crucial for life science advancements. ATGen manufactures and distributes a large selection of recombinant proteins and monoclonal antibodies to over 200 research institutes in over 20 different countries.

Atgen的主要产品包括：

Neuroscience

Immunology

Glycobiology

Heat Shock Proteins

Cancer

Apoptosis

Signal Transduction

Transcription & Translation

Proteases & Inhibitors

Growth factors 

Accurate Chemical & Scientific Corporation公司成立于1974年，标准化流程生产高质量多克隆和单克隆抗体。公司市场覆盖广泛客户群体和应用领域，未政府实验室、大学研究中心、制药实验室以及医院临床中心服务。

1974 saw the incorporation of Accurate Chemical & Scientific Corporation. Accurate pioneered and introduced standardized, highly characterized polyclonal and monoclonal antibodies. Since 1975, Accurate has specialized in products for basic and R&D research as well as routine laboratory work. Accurate's market covers a broad range of customers and applications, serving government labs, university research centers, pharmaceutical laboratories, as well as hospitals, clinical and industrial centers.

Accurate chemical公司的主要产品包括：

Antibodies and Antigens

Monoclonal antibodies

Polyclonal antibodies

Lab Equipment

Biocolor Assay Kits

Cell Separation Media

艾美捷科技特约代理Avidity Biosciences公司产品。

Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

Antibody oligonucleotide conjugate (AOC™) technology

Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.